Preview

Медицинский Совет

Расширенный поиск

Возможности коррекции гиперурикемии при метаболическом синдроме

https://doi.org/10.21518/2079-701X-2014-2-18-25

Полный текст:

Аннотация

Метаболический синдром (МС) имеет многогранный патогенез, в большинстве механизмов которого так или иначе участвует мочевая кислота. Активную роль избыток уратов играет в процессе воспаления, эндотелиальной дисфункции, атерогенезе, инсулинорезистентности. Нацеленность на выявление гиперурикемии является инструментом успешного контроля сердечно-сосудистого риска. Выбор антигипертензивных и гиполипидемических препаратов при МС должен определяться их способностью контролировать уровень мочевой кислоты сыворотки крови.

Об авторах

С. В. Недогода
Волгоградский государственный медицинский университет
Россия


А. С. Саласюк
Волгоградский государственный медицинский университет
Россия


И. Н. Барыкина
Волгоградский государственный медицинский университет
Россия


А. А. Ледяева
Волгоградский государственный медицинский университет
Россия


В. В. Цома
Волгоградский государственный медицинский университет
Россия


Е. В. Чумачек
Волгоградский государственный медицинский университет
Россия


В. Ю. Хрипаева
Волгоградский государственный медицинский университет
Россия


Список литературы

1. Барскова В.Г., Насонова В.А. Подагра и синдром инсулинорезистентности. Русский медицинский журнал, 2003, 23: 12-20.

2. Гиперурикемия, артериальная гипертензия и хроническая болезнь почек: интерпретация взаимосвязи и стратегия действий. Клиническая нефрология, 2010, 4: 4-11.

3. Джанашия П.Х., Диденко В.А. Является ли гиперурикемия компонентом метаболического синдрома? Российский кардиологический журнал. 2001, 1: 15-19.

4. Кобалава ЖД., Толкачева В.В. Мочевая кислота - независимый предиктор сердечно-сосудистых событий. Урикозурический потенциал лозартана. Клиническая фармакология и терапия, 2011, 3: 1-9.

5. Кобалава ЖД, Толкачева В.В. Феномен лозартан-индуцированной урикозурии и гипоурикемии: патофизиологические механизмы и клиническое значение. Часть II. Клиническая фармакология и терапия, 2003, 4: 14-17.

6. Лебедева М.В., Стахова Т.Ю., Балкаров И.М., Минакова Е.Г., Зайцева Л.И., Северова М.М., Шовская Т.Н. Альбуминурия, плазменная концентрация эндотелина-1 и атеросклеротическое поражение сонных артерий у больных артериальной гипертензией и гиперурикемией. Клиническая нефрология, 2009, 3: 57-61.

7. Abreu E, Fonseca MJ, Santos AC. Association between hyperuricemia and insulin resistance. Acta Med Port, 2011, 2: 565-574.

8. Alderman M, Cohen H, Madhavan S, Kivlighn S. Serum Uric Acid and Cardiovascular Events in Successfully Treated Hypertensive. Hypertension, 1999, 34: 144-150.

9. Alderman MH, Cohen H, Madhavan S. Distribution and determinants of cardiovascular events during 20 years of successful antihypertensive treatment. J. Hypertens, 1998, 16: 761-769.

10. Athyros VG, Karagiannis A, Ganotakis ES. Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study Curr Med Res Opin, 2011, 27: 1659-1668.

11. Athyros VG, Papageorgiou AA, Symeonidis AN. Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus. A subgroup analysis of the GREek Atorvastatin and Coronary-Heart-Disease Evaluation (GREACE) study. Angiology, 2003, 54: 679-690.

12. Beavers KM, Beavers DP, Serra MC. Low relative skeletal muscle mass indicative of sarcopenia is associated with elevations in serum uric acid levels: Findings from NHANES III. Journal of nutrition, health & aging, 2009, 3: 177-182.

13. Bedir А, Topbas M, Tanyeri F, Alvur M, Arik N. Leptin Might be a Regulator of Serum Uric Acid Concentrations in Humans. Jpn Heart J, 2003, 4: 527-36.

14. Bonora E, Targher G, Zenere MB, Saggiani F. Relationship of uric acid concentration to cardiovascular risk factors in young men. Role of obesity and central fat distribution. The Verona Young Men Atherosclerosis Risk Factors Study. Int J Obes Relat Metab Disord, 1996, 11: 975-980.

15. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress. Circ Res, 2000, 87: 840-844.

16. Chen L, Zhu W, Chen Z, Dai H, Ren J, Chen J. Relationship between hyperuricemia and metabolic syndrome. J Zhejiang Univ Sci B, 2007, 8: 593-598.

17. Cohen E, Krause I, Fraser A, Goldberg E, Garty M. Hyperuricemia and Metabolic Syndrome: Lessons from aLarge Cohort from Israel. IMAJ, 2012, 14: 676-680.

18. Conen D, Wietlisbach V, Bovet P, Shamlaye C, Riesen W, Paccaud F. Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. BMC Public Health, 2004, 4: 9-15.

19. Cornier M, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ. The Metabolic Syndrome. Endocrine Reviews, 2008, 7; 777-822.

20. Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation, 2002, 106: 2085-2090.

21. Cuenca А, Rolda V, Marı´n F. Hypouricemic effect of statins: another pleiotropic benefit? Journal of Thoracic and Cardiovascular Surgery, 2010, 5: 1358-1359.

22. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med, 1999, 131: 7-13.

23. Delles C, Schneider MP, John S, Gekle M, Schmieder RE. Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical N(G), N(G)-dimethylarginine in human essential hypertension. Am J Hypertens, 2002, 15: 590-593.

24. Evans JL, Maddux BA, Goldfine ID. The molecular basis for oxidative stressinduced insulin resistance. Antioxid Redox Signal, 2005, 7: 1040-1052.

25. Giacomello A, Sciascio N, Quaratino C. Relation between serum triglyceride level, serum urate concentration, and fractional urate excretion. Metabolism Clinical and Experimental, 1997, 46: 1085-1089.

26. Goya W, Shaper G, Whincup P. Serum urate and the risk of major coronary heart disease events. Heart, 1997, 78: 147-153.

27. Higashi Y, Noma K, Yoshizumi M, Kihara Y. Endothelial Function and Oxidative Stress in Cardiovascular Diseases. Circ J, 2009, 73: 411-418.

28. Hikita M, Ohno I, Mori Y, Ichida K, Yokose T, Hosoya T. Relationship between hyperuricemia and body fat distribution. Intern Med, 2007, 46: 1353-1358.

29. Ho W, Tsai W, Yu K, Tsay P, Wang C, Hsu T, Kuo C. Association between endothelial dysfunction and hyperuricaemia. Rheumatology, 2010, 10: 1929-1934.

30. Hoieggen A, Alderman M, Kjeldsen S, Julius S, Devereux R, Faire U, Fyhrquist F, Ibsen H, Kristianson K. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney International, 2004, 65: 1041-1049.

31. Ishizaka N, Ishizaka Y, Toda E, Nagai R, Yamakado M. Association Between Serum Uric Acid, Metabolic Syndrome, and Carotid Atherosclerosis in Japanese Individuals. Arterioscler Thromb Vasc Biol, 2005, 25: 1038-1044.

32. Johnson R, Segal M, Srinivas T, Ejaz A, Mu W, Roncal C, Sa´nchez-Lozada L, Gersch M, Rodriguez-Iturbe B, Kang D, Acosta J. Essential Hypertension, Progressive Renal Disease, and Uric Acid: A Pathogenetic Link? J Am Soc Nephrol., 2005, 16: 1909-1919.

33. Johnson R, Kang D, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle K, Rodriguez-Iturbe B, Herrera-Acosta J, Mazzali M. Is There a Pathogenetic Role for Uric Acid in Hypertension and Cardiovascular and Renal Disease? Hypertension, 2003, 4: 1183-1190.

34. Kanbay M, Huddam B, Azak A, Solak Y, Kadioglu GK, Kirbas I, Duranay M, Covic A, Johnson RJ. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol., 2011, 8: 1887-1894.

35. Kansui Y, Ohtsubo T, Goto K, Sakata S, Ichishima K, Fukuhara M, Ohta Y, Matsumura K. Association of Serum Uric Acid With Blood Pressure in Japanese Men. Circulation Journal, 2011, 12: 2827-32.

36. Kato M, Hisatome I, Tomikura Y, Kotani K, Kinugawa T, Ogino K, Ishida K, Igawa O, Shigemasa C, Somers VK. Status of endothelial dependent vasodilation in patients with hyperuricemia. Am J Cardiol., 2005, 11: 1576-1580.

37. Koch А, Weiskirchen R, Sanson E, Zimmermann H, Voigt S, Dückers H, Trautwein C, Tacke F. Circulating retinol binding protein 4 in critically ill patients before specific treatment: prognostic impact and correlation with organ function, metabolism and inflammation. Critical Care, 2010, 14: 179-184.

38. Kostka-Jeziorny K, Uruski P, Tykarski A. Effect of allopurinol on blood pressure and aortic compliance in hypertensive patients. Blood Press, 2011, 2: 104-110.

39. Landmesser U, Spiekermann S, Dikalov S. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxiddysmutase. Circulation, 2002, 106: 3073-3078.

40. Lee JM, Chang KH, Cho HM, Oh SM, Choi DP, Suh Il. Association between Serum uric acid level and metabolic syndrome. J Prev Med Public Health, 2012, 3: 181-187.

41. Li Q, Yang Z, Lu B, Wen J, Ye Z, Chen L, He M, Tao X, Zhang W, Huang Y, Zhang Z, Qu S, Hu R. Serum uric acid level and its association with metabolic syndrome and carotid atherosclerosis in patients with type 2 diabetes. Cardiovasc Diabetol, 201, 10: 72.

42. Lyngdoh T, Marques-Vidal P, Paccaud F, Preisig M, Waeber G, Bochud M, Vollenweider P. Elevated serum uric acid is associated with high circulating inflammatory cytokines in the population-based colaus. PLoS One, 2011, 5: 33-38.

43. Matsuura F, Yamashita S, Nakamura T, Nishida M, Nozaki S, Funahashi T, Matsuzawa Y. Effect of visceral fat accumulation on uric acid metabolism in male obese subjects: visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat. Metabolism, 1998, 8: 929-933.

44. Mercuro G, Vitale C, Cerquetani E, Zoncu S, Deidda M, Fini M, Rosano GM. Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am J Cardiol, 2004, 7: 932-935.

45. Milionis H, Kakafika AI, Tsouli S, Athyros V, Bairaktari E, Seferiadis KI, Elisaf M. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. American Heart Journal, 2004, 4: 635-640.

46. Milionis HJ, Rizos E, Kostapanos M. Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). Curr Med Res Opin, 2006, 22: 1123-1131.

47. Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, Glushakova O, Ouyang X, Feig DI, Block ER, Herrera-Acosta J. A causal role for uric acid in fructose-induced metabolic syndrome. J Physiol Renal Physiol, 2006, 3: 625-631.

48. Nakashima M, Uematsu T, Kosuge K, Kanamaru M. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur. J. Clin. Pharmacol, 1992, 42: 333-335.

49. Obermayr R, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R. Elevated Uric Acid Increases the Risk for Kidney Disease. Am Soc Nephrol, 2008, 12: 2407-2413.

50. Oda E, Kawai R, Sukumaran V, Watanabe K. Uric acid is positively associated with metabolic syndrome but negatively associated with diabetes in Japanese men. Intern Med, 2009, 48: 1785-1791.

51. Ogata N, Fujimori S, Oka Y. Effects of three strong statins (atorvastatin, pitavastatin, rosuvastatin) on serum uric acid levels in dyslipidemic patients. Nucleosides Nucleotides Nucleic Acids, 2010, 29: 321-324.

52. Oliveira E, Moreto F, Burini R. Dietary, anthropometric, and biochemical determinants of uric acid in free-living adults. Nutrition Journal, 2013, 12: 11.

53. Onat A, Uyarel H, Hergenç G, Karabulut A, Albayrak S, Sari I. Serum uric acid is a determinant of metabolic syndrome in a population-based study. Am J Hypertens, 2006, 19: 1055-1062.

54. Park C, Shin WS, Kim PJ, Chang K, Kim HY, Youn HJ, Chung WS, Seung KB, Kim JH. Relationship Between Plasma Adiponectin, Retinol-Binding Protein 4 and Uric Acid in Hypertensive Patients With Metabolic Syndrome. Korean Circ J, 2011, 4: 198-202.

55. Puig JG, Martínez MA, Mora M. Serum urate, metabolic syndrome and cardiovascular risk factors: a population-based study. Nucleos Nucleot Nucl, 2008, 6: 620-623.

56. Riggiero C, Cherubini A, Ble A. Uric acid and inflammatory markers. Eur Heart J, 2006, 10: 1174-1181.

57. Ripley E, Hirsch А. Fifteen years of losartan: what have we learned about losartan that can benefit chronic kidney disease patients? Int J Nephrol Renovasc Dis, 2010, 3: 93-98.

58. Saku K, Zhang B, Noda K. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial Circ J, 2011, 75: 1493-1505.

59. Salehidoost R, Aminorroaya A, Zare M. Is uric acid an indicator of metabolic syndrome in the first-degree relatives of patients with type 2 diabetes? J Res Med Sci, 2012, 11: 1005-1010.

60. See LC, Kuo CF, Chuang FH, Shen YM, Ko YS, Chen YM, Yu KH. Hyperuricemia and metabolic syndrome: associations with chronic kidney disease. Clin Rheumatol, 2011, 30(3): 323-330.

61. Sweet C, Bradstreet D, Berman R. Pharmacodynamic activity of intravenous E-3174, an angiotensin II receptor antagonist, in patients with essential hypertension. Am. J. Hypertens, 1994, 7: 1035-1040.

62. Takagi H, Umemoto T. Atorvastatin therapy reduces serum uric acid levels: A meta-analysis of randomized controlled trials. International Journal of Cardiology, 2012, 2: 255-257.

63. Tsai WC, Huang YY, Lin CC, Li WT, Lee CH, Chen JY, Chen JH. Uric acid is an independent predictor of arterial stiffness in hypertensive patients. Heart Vessels, 2009, 5: 371-375.

64. Tsioufis C, Chatzis D, Vezali E, Dimitriadis K, Antoniadis D, Zervoudaki A, Lalos S, Kallikazaros I, Stefanadis C, Toutouzas P. The controversial role of serum uric acid in essential hypertension: relationships with indices of target organ damage. J Hum Hypertens, 2005, 3: 211-217.

65. Tsioufis C, Kyvelou S, Dimitriadis K, Syrseloudis D, Sideris S, Skiadas I, Katsi V, Stefanadi E, Lalos S, Mihas C, Poulakis M, Stefanadis C. The diverse associations of uric acid with low-grade inflammation, adiponectin and arterial stiffness in never-treated hypertensives. Journal of Human Hypertension, 2011, 25: 554-559.

66. Tsunoda K, Abe K. Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in hypertension. J. Hypertens, 1993, 6: 28-32.

67. Vekic J, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V, Memon L, Zeljkovic A, Bogavac-Stanojevic N, Spasic S. High serum uric acid and low-grade inflammation are associated with smaller LDL and HDL particles. Atherosclerosis, 2009, 1: 236-242.

68. Viazzi F, Parodi D, Leoncini G, Parodi A, Falqui V, Ratto E, Vettoretti S, Bezante G, Sette M, Deferrari G, Pontremoli R. Serum Uric Acid and Target Organ Damage in Primary Hypertension. Hypertension, 2005, 45: 991-998.

69. Vlachopoulos C, Xaplanteris P, Vyssoulis G, Bratsas A, Baou K, Tzamou V, Aznaouridis K, Dima I, Lazaros G, Stefanadis C. Association of Serum Uric Acid Level With Aortic Stiffness and Arterial Wave Reflections in Newly Diagnosed, Never-Treated Hypertension. American Journal of Hypertension, 2011, 24: 33-39.

70. Wolf G. Serum retinol-binding protein: a link between obesity, insulin resistance, and type 2 diabetes. Nutr Rev, 2007, 5: 251-256.

71. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L, Kahn BB. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature, 2005, 436: 356-362.

72. Yoo TW, Sung KC, Shin HS, Kim BJ. Relationship Between Serum Uric Acid Concentration and Insulin Resistance and Metabolic Syndrome. Circ J, 2005, 69: 928-933.

73. Zapolski T, Waciński P, Kondracki B, Rychta E, Buraczyńska M, Wysokiński A. Uric acid as a link between renal dysfunction and both pro−inflammatory and prothrombotic state in patients with metabolic syndrome and coronary artery disease. Kardiologia Polska, 2011, 4: 319-326.

74. Zhang ML, Gao YX, Wang X. Serum uric acid and appropriate cutoff value for prediction of metabolic syndrome among Chinese adults. J Clin Biochem Nutr, 2013, 1: 38-42.

75. Zoccali C, Maio R, Mallamaci F, Sesti G, Perticone F. Uric Acid and Endothelial Dysfunction in Essential Hypertension. JASN, 2006, 5:1466-1471.


Просмотров: 80


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)